CHMP OKs Actelion's Zavesca for NPC

15 January 2009

Swiss drugmaker Actelion says that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an  extension of indication for the use of Zavesca (miglustat) in patients  suffering from Niemann-Pick type C, a very rare neurodegenerative  genetic disease.

Based on the CHMP opinion, the European Commission is expected to make a  final decision within two months. Actelion is currently evaluating the  possibility for submissions for the agent in NPC in other countries  outside the European Union.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight